These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 21057906

  • 1. Characterisation and deposition studies of recrystallised lactose from binary mixtures of ethanol/butanol for improved drug delivery from dry powder inhalers.
    Kaialy W, Martin GP, Ticehurst MD, Royall P, Mohammad MA, Murphy J, Nokhodchi A.
    AAPS J; 2011 Mar; 13(1):30-43. PubMed ID: 21057906
    [Abstract] [Full Text] [Related]

  • 2. Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol-acetone.
    Kaialy W, Ticehurst MD, Murphy J, Nokhodchi A.
    J Pharm Sci; 2011 Jul; 100(7):2665-84. PubMed ID: 21268026
    [Abstract] [Full Text] [Related]

  • 3. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
    Kaialy W, Martin GP, Larhrib H, Ticehurst MD, Kolosionek E, Nokhodchi A.
    Colloids Surf B Biointerfaces; 2012 Jan 01; 89():29-39. PubMed ID: 21962946
    [Abstract] [Full Text] [Related]

  • 4. The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient.
    Kaialy W, Martin GP, Ticehurst MD, Momin MN, Nokhodchi A.
    Int J Pharm; 2010 Jun 15; 392(1-2):178-88. PubMed ID: 20363301
    [Abstract] [Full Text] [Related]

  • 5. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM, MacRitchie HB, Marriott C, Martin GP.
    Int J Pharm; 2007 Mar 21; 333(1-2):45-55. PubMed ID: 17064863
    [Abstract] [Full Text] [Related]

  • 6. Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler.
    Kaialy W, Momin MN, Ticehurst MD, Murphy J, Nokhodchi A.
    Colloids Surf B Biointerfaces; 2010 Sep 01; 79(2):345-56. PubMed ID: 20537870
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antisolvent crystallisation is a potential technique to prepare engineered lactose with promising aerosolisation properties: effect of saturation degree.
    Kaialy W, Nokhodchi A.
    Int J Pharm; 2012 Nov 01; 437(1-2):57-69. PubMed ID: 22884837
    [Abstract] [Full Text] [Related]

  • 9. Characterisation and deposition studies of engineered lactose crystals with potential for use as a carrier for aerosolised salbutamol sulfate from dry powder inhalers.
    Larhrib H, Martin GP, Prime D, Marriott C.
    Eur J Pharm Sci; 2003 Jul 01; 19(4):211-21. PubMed ID: 12885385
    [Abstract] [Full Text] [Related]

  • 10. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
    Kaialy W, Ticehurst M, Nokhodchi A.
    Int J Pharm; 2012 Feb 28; 423(2):184-94. PubMed ID: 22197772
    [Abstract] [Full Text] [Related]

  • 11. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ, Jain RR, Soni PS, Abdul S, Darshana H, Gaikwad RV, Menon MD.
    J Aerosol Med Pulm Drug Deliv; 2015 Aug 28; 28(4):254-67. PubMed ID: 25517187
    [Abstract] [Full Text] [Related]

  • 12. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers.
    Corrigan DO, Corrigan OI, Healy AM.
    Int J Pharm; 2006 Sep 28; 322(1-2):22-30. PubMed ID: 16815654
    [Abstract] [Full Text] [Related]

  • 13. Interaction of Formulation and Device Factors Determine the In Vitro Performance of Salbutamol Sulphate Dry Powders for Inhalation.
    Muddle J, Murnane D, Parisini I, Brown M, Page C, Forbes B.
    J Pharm Sci; 2015 Nov 28; 104(11):3861-3869. PubMed ID: 26220184
    [Abstract] [Full Text] [Related]

  • 14. The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate.
    Larhrib H, Zeng XM, Martin GP, Marriott C, Pritchard J.
    Int J Pharm; 1999 Nov 25; 191(1):1-14. PubMed ID: 10556735
    [Abstract] [Full Text] [Related]

  • 15. Effect of carrier particle shape on dry powder inhaler performance.
    Kaialy W, Alhalaweh A, Velaga SP, Nokhodchi A.
    Int J Pharm; 2011 Dec 12; 421(1):12-23. PubMed ID: 21945739
    [Abstract] [Full Text] [Related]

  • 16. The influence of carrier and drug morphology on drug delivery from dry powder formulations.
    Larhrib H, Martin GP, Marriott C, Prime D.
    Int J Pharm; 2003 May 12; 257(1-2):283-96. PubMed ID: 12711183
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of Granulated Lactose as a Carrier for Dry Powder Inhaler Formulations 2: Effect of Drugs and Drug Loading.
    Du P, Du J, Smyth HDC.
    J Pharm Sci; 2017 Jan 12; 106(1):366-376. PubMed ID: 27939234
    [Abstract] [Full Text] [Related]

  • 18. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 1. Albuterol sulfate and disodium cromoglycate.
    Xu Z, Mansour HM, Mulder T, McLean R, Langridge J, Hickey AJ.
    J Pharm Sci; 2010 Aug 12; 99(8):3398-414. PubMed ID: 20198688
    [Abstract] [Full Text] [Related]

  • 19. The influence of carrier morphology on drug delivery by dry powder inhalers.
    Zeng XM, Martin GP, Marriott C, Pritchard J.
    Int J Pharm; 2000 Apr 25; 200(1):93-106. PubMed ID: 10845690
    [Abstract] [Full Text] [Related]

  • 20. Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation.
    Zeng XM, Martin GP, Tee SK, Ghoush AA, Marriott C.
    Int J Pharm; 1999 May 25; 182(2):133-44. PubMed ID: 10341303
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.